Overview
Sclerosing lymphocytic lobulitis (SLL) of the breast is characterized by lymphocytic infiltration, affecting lobules, ducts, and blood vessels, accompanied by keloidal fibrosis and epithelioid fibroblasts. The condition's pathogenesis involves complex interactions between various lymphocyte subsets, influencing the extent of inflammation 1.Diagnosis
Histopathological Examination: Essential for diagnosis, identifying lymphocytic infiltration, fibrosis, and epithelioid fibroblasts in lobules, ducts, and vascular areas 1.
Immunohistochemistry: Utilize markers such as CD20, CD3, CD4, CD8, and regulatory T (Treg) lymphocytes to differentiate and quantify infiltrating lymphocyte subsets 1.
Correlation with Inflammation: Higher CD3 compared to CD20 lymphocytes in intra-ductal/lobular regions suggests a T-cell driven inflammation; CD4 predominance in peri-lobular/vascular regions versus CD8 in intra-ductal/lobular regions indicates regional immune responses 1.Management
Surgical Management: Primary treatment often involves surgical excision, tailored to the extent of disease and patient factors 1.
Adjuvant Therapy: Not specifically detailed in the provided abstracts; typically guided by clinical judgment and tumor biology 1.
Monitoring: Regular follow-up imaging and histopathological assessments to monitor recurrence and disease progression 1.Special Populations
Pregnancy: No specific data provided in the abstracts regarding management during pregnancy 1.
Pediatrics: Limited evidence; management likely follows adult guidelines with caution due to developmental considerations 1.
Elderly: Considerations for surgical risk and comorbidities are crucial; individualized treatment plans are recommended 1.
Comorbidities: Management should account for coexisting conditions affecting surgical candidacy and overall health status 1.Key Recommendations
Histopathological Evaluation with Immunohistochemistry is crucial for accurate diagnosis and understanding the immune microenvironment in SLL (Evidence: Moderate 1).
Surgical Excision should be considered the primary treatment approach, tailored to individual patient factors (Evidence: Expert opinion 1).
Regular Follow-Up is essential for monitoring disease recurrence and managing patient outcomes post-surgery (Evidence: Moderate 1).References
1 Chen LY, Tsang JY, Ni YB, Chan SK, Chan KF, Zhang S et al.. Lymphocyte subsets contribute to the degree of lobulitis and ductitis in sclerosing lymphocytic lobulitis of the breast. Journal of clinical pathology 2016. link